From the publishers of JADPRO

Metastatic Triple-Negative Breast Cancer Resource Center

Advertisement

Immunotherapy Treatment for Triple Negative Breast Cancer

Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of breast cancer and has dismal prognosis. In this review, the authors summarize the trials using checkpoint therapy in early and metastatic TNBC, as well as the development of biomarkers and the importance of immune related adverse events (IRAEs), in this disease process.

Pharmaceuticals
Advertisement
News & Literature Highlights
Advertisement
Advertisement